JBCPL: KKR-backed JBCPL unveils new logo & identity

JB Chemical substances & Prescribed drugs (JBCPL) on Friday unveiled a brand new emblem and identification because the 45-year previous firm backed by PE agency KKR is attempting to evolve as per affected person wants with an aggressive India focussed technique.

JBCPL will now be recognized as JB and with a motto of ‘Good Individuals for Good Well being’.

“In 45 years, we at JB have constructed a powerful basis of integrity, belief and reliability. Now we’re taking the following leap ahead in the direction of changing into extra agile, lean and easy,” stated Nikhil Chopra, CEO & whole-time director of JB.

“Our choices and capabilities have gotten extra numerous to cater to the evolving wants of our prospects, our manufacturing processes have gotten extra strong, and lean, and our imaginative and prescient of wanting on the healthcare business is changing into extra progressive globally,” Chopra stated.

Other than including line extensions and coming into new therapeutic segments comparable to diabetes, nephrology, respiratory – JB has invested Rs 1000 crore to fund acquisitions of Sanzyme portfolio of probiotics and coronary heart failure drug Azmarda from

.

Chopra stated the acquisitions have helped JB to develop the share of continual section from 46% to 54% with a watch on reaching 60%.

JB which is ranked 25 in Indian pharmaceutical market has moved 9 ranks forward, with 5 of its manufacturers in prime 300, as per market analysis agency AIOCD. JB’s home formulation enterprise grew at 33.6% in comparison with business progress of 27.9%.

Chopra stated JB plans to have at the least 7 manufacturers in prime 300 by finish of FY23.

Within the monetary yr 2021-22, the corporate recorded income of Rs 2424 crores as in comparison with Rs 2043 crores in FY 2020-21, registering a progress of 19%.